JAMIE ZURCHER: Open Payments
NPI 1093046534 · GRAVOIS MILLS, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$810 in 38 payments from 14 companies in 2025. Trend: 2023 $351 · 2024 $679 · 2025 $810
Food & beverage: $810
| Company | Payments | Amount |
|---|---|---|
| Dexcom, Inc. | 7 | $159 |
| Neurocrine BioSciences, Inc. | 5 | $120 |
| Vanda Pharmaceuticals Inc. | 3 | $90 |
| E.R. Squibb & Sons, L.L.C. | 4 | $69 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $69 |
| ABBVIE INC. | 3 | $54 |
| Otsuka America Pharmaceutical, Inc. | 3 | $48 |
| Novo Nordisk Inc | 2 | $47 |
| Alkermes, Inc. | 2 | $43 |
| AstraZeneca Pharmaceuticals LP | 1 | $33 |
Products named: Dexcom G6 Transmitter, INGREZZA, FANAPT, COBENFY, CAPLYTA, Wegovy, ABILIFY MAINTENA, BREZTRI.
Industry payments across MO — which companies pay providers there.
